PMID- 27387522
OWN - NLM
STAT- MEDLINE
DCOM- 20180809
LR  - 20240130
IS  - 1532-6551 (Electronic)
IS  - 1071-3581 (Linking)
VI  - 24
IP  - 6
DP  - 2017 Dec
TI  - Adaptive servo-ventilation therapy improves cardiac sympathetic nerve activity, 
      cardiac function, exercise capacity, and symptom in patients with chronic heart 
      failure and Cheyne-Stokes respiration.
PG  - 1926-1937
LID - 10.1007/s12350-016-0529-9 [doi]
AB  - PURPOSE: Adaptive servo-ventilation (ASV) therapy has been reported to be 
      effective for improving central sleep apnea (CSA) and chronic heart failure 
      (CHF). The purpose of this study was to clarify whether ASV is effective for CSA, 
      cardiac sympathetic nerve activity (CSNA), cardiac symptoms/function, and 
      exercise capacity in CHF patients with CSA and Cheyne-Stokes respiration 
      (CSR-CSA). METHODS: In this study, 31 CHF patients with CSR-CSA and a left 
      ventricular ejection fraction (LVEF) </= 40% were randomized into an ASV group and 
      a conservative therapy (non-ASV) group for 6 month. Nuclear imagings with 
      (123)I-Metaiodobenzylguanidine (MIBG) and (99m)Tc-Sestamibi were performed. 
      Exercise capacity using a specific activity scale (SAS) and the New York Heart 
      Association (NYHA) class were evaluated. CSNA was evaluated by (123)I-MIBG 
      imaging, with the delayed heart/mediastinum activity ratio (H/M), delayed total 
      defect score (TDS), and washout rate (WR). RESULTS: The ASV group had 
      significantly better (P < .05) results than the non-ASV group with respect to the 
      changes of AHI (-20.8 +/- 14.6 vs -0.5 +/- 8.1), TDS (-7.9 +/- 4.3 vs 1.4 +/- 6.0), and 
      H/M(0.16 +/- 0.16 vs -0.04 +/- 0.10) on (123)I-MIBG imaging, as well as the changes 
      of LVEF (5.3 +/- 3.9% vs 0.7 +/- 32.6%), SAS (1.6 +/- 1.4 vs 0.3 +/- 0.7), and NYHA class 
      (2.2 +/- 0.4 vs 2.7 +/- 0.5) after 6-month therapy. CONCLUSIONS: Performing ASV for 
      6 months achieved improvement of CSR-CSA, CSNA, cardiac symptoms/function, and 
      exercise capacity in CHF patients with CSR-CSA.
FAU - Toyama, Takuji
AU  - Toyama T
AD  - Toyama Cardiovasucular Clinic, 2-33-9, Aramaki-machi, Maebashi, Gunma, 371-0044, 
      Japan. t.toyama@toyama-clinic.jp.
FAU - Hoshizaki, Hiroshi
AU  - Hoshizaki H
AD  - Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Kasama, Shu
AU  - Kasama S
AD  - Department of Cardiovascular Medicine, Gunma University School of Medicine, 
      Maebashi, Japan.
FAU - Miyaishi, Yusuke
AU  - Miyaishi Y
AD  - Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Kan, Hakuken
AU  - Kan H
AD  - Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Yamashita, Eiji
AU  - Yamashita E
AD  - Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Kawaguti, Ren
AU  - Kawaguti R
AD  - Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Adachi, Hitoshi
AU  - Adachi H
AD  - Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Ohsima, Shigeru
AU  - Ohsima S
AD  - Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160707
PL  - United States
TA  - J Nucl Cardiol
JT  - Journal of nuclear cardiology : official publication of the American Society of 
      Nuclear Cardiology
JID - 9423534
RN  - 35MRW7B4AD (3-Iodobenzylguanidine)
SB  - IM
CIN - J Nucl Cardiol. 2017 Dec;24(6):1938-1940. PMID: 27457530
MH  - 3-Iodobenzylguanidine
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cheyne-Stokes Respiration/diagnostic imaging/physiopathology/*therapy
MH  - Chronic Disease
MH  - *Exercise
MH  - Female
MH  - Heart/*innervation/physiopathology
MH  - Heart Failure/diagnostic imaging/physiopathology/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Respiration, Artificial/*methods
MH  - Sympathetic Nervous System/*physiopathology
OTO - NOTNLM
OT  - Adaptive servo-ventilation
OT  - cardiac sympathetic nerve activity
OT  - chronic heart failure and cheyne-Stokes respiration
EDAT- 2016/07/09 06:00
MHDA- 2018/08/10 06:00
CRDT- 2016/07/09 06:00
PHST- 2015/06/14 00:00 [received]
PHST- 2016/04/05 00:00 [revised]
PHST- 2016/07/09 06:00 [pubmed]
PHST- 2018/08/10 06:00 [medline]
PHST- 2016/07/09 06:00 [entrez]
AID - S1071-3581(23)06721-1 [pii]
AID - 10.1007/s12350-016-0529-9 [doi]
PST - ppublish
SO  - J Nucl Cardiol. 2017 Dec;24(6):1926-1937. doi: 10.1007/s12350-016-0529-9. Epub 
      2016 Jul 7.